What is CRIZOCENT 250 mg?

CRIZOCENT 250 mg belongs to the class of kinase inhibitors. It blocks the signal cancer cells get for growing and multiplying. It slows down or stops tumor growth. It acts by inhibiting ALK and ROS1 mutations. This medication is indicated when lung cancer has spread to other parts of the body.

 

Dosage and Administration

Recommended Dose:

• Non-Small Cell Lung Cancer (NSCLC): 250 mg twice daily until disease progression or unacceptable toxicity.

 

Dosage and Administration

• Administer CRIZOCENT 250 mg orally with or without food.
• Administer the capsule whole with water.
• Administered at the same time of day once daily.
• If a dose is missed by more than 6 hours, then omit the missed dose and continue the next scheduled dose.

 

Benefits

• Tumor Reduction: Shrinks the size of the tumor and thus delays its growth.
• Prolonged Survival: Improves life expectancy and improves the quality of life.
• Fewer Side Effects: Less general side effects are produced by     CRIZOCENT 250 mg as compared to chemotherapy.
• Negligible Damage to Normal Cells: CRIZOCENT acts against cancerous cells while normal tissues are preserved. Its general toxicity is reduced too.
• Quick Onset of Action: Tumor shrinkage may be seen in a few weeks following the initiation of therapy in many cases.
• Brain Metastases: CRIZOCENT was also effective in the metastasis of lung cancer to the brain.

Clinical Evidence

• The Profile 1014 trial demonstrated a statistically significant improvement in progression-free survival among ALK-positive NSCLC patients. 
• Profile 1001 trial: It was also associated with quite striking responses among ROS1-positive NSCLC patients.
• PROFILE 1005 TRIAL: It presented the efficacy of CRIZOCENT in previously treated patients with advanced lung cancer.
• REAL-WORLD DATA: Studies have evidenced long-term benefit in patients on CRIZOCENT 250 mg in the real world outside of clinical trials.

Side Effects

Common Side Effects:

• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Vision disorders

Serious Side Effects:

• Hepatotoxicity
• QT prolongation
• Pneumonitis
• Bradycardia
• Neutropenia
• Gastrointestinal Problems: Painful abdomen or constipation
• Edema: Edema of hands, feet, or lower legs.

Precautions

• Liver Monitoring: The drug should be given cautiously to the patient along with periodic monitoring of his liver.
• Cardiac Monitoring: Routine monitoring of QT prolongation in the patient.
• Monitoring of Pulmonary Function: A symptom of early stages of pneumonitis in lungs.

 

Patient-centered Approach

A dosage of 250 mg of CRIZOCENT, based on the result of the genetic test, is formulated. Adverse reactions are closely monitored with a view to managing and optimizing treatment.

 

Storage Instructions

• Store at 20-25°C
• Keep away from moisture and light
• Store in the same container
• Keep out of the reach of children
• Do not freeze or expose to extreme heat

 

Mechanism of Action

Crizocent 250 mg works in human bodies by selectively inhibiting the activity caused due to proliferation and growth that results from a mutation of ALK and ROS1 genes. Most tumor cells are targeted, sparing the normal cells. It has been found that these kinds of inhibition of those kinases induce apoptosis on these oncological cells.

 

Long-Term Benefits

Long-term responses are seen in lung cancer patients treated with         CRIZOCENT 250 mg. There is an improvement cycle in survival and quality of life since it deals with the molecular cause of the disease. Patients reported that the remission period was longer, with minimum frequency of hospitalisation.

Post-Marketing Surveillance

Safety and efficacy of CRIZOCENT 250 mg has also been established through the post-marketing data. The ongoing studies depict its long-term effects. The focus of monitoring includes rare adverse events and patient-reported outcomes.

Emerging Indications

Other new indications for CRIZOCENT 250 mg include lymphoma and malignancies in the pediatric population. Its use in combination with immunotherapy is under investigation. Its role in some other rare ALK-driven cancers outside the lungs is also being evaluated in trials.

 

Drug Resistance and CRIZOCENT 250 mg

Some cancers may become resistant to CRIZOCENT over time. New combinations of treatment and second-generation ALK inhibitors overcome resistance.Biomarkers that predict the development of resistance are being discovered so that intervention may be carried out even earlier.

 

Supportive Care throughout Treatment

It is possible to give medication against nausea, dietary support, and follow-ups. Supportive care improves adherence to therapy and is associated with improvement in well-being. Recommendations for psychological support and pain management strategies were also suggested.

 

Genetic Testing and CRIZOCENT 250 mg Eligibility

Genetic testing will determine the presence of ALK or ROS1 mutations. Such determinants mean that oncologists can look to identify those patients who will receive maximum benefit if prescribed CRIZOCENT 250mg. Testing could involve blood samples or tumor biopsies.

 

Patient Testimonials

From the testimonials, it comes out that following the administration of    CRIZOCENT 250 mg. The size of the tumour has reduced in size, fewer symptoms are being experienced, and the energy levels have increased. Most of the patients expressed satisfaction with the results of the treatment. The testimonials indicate improved general health, reduced pain, and more productivity at work or in socializing.

 

Physician Insights

Physicians here believe that the real game-changing power of CRIZOCENT 250 mg seems to be in the management of the advanced varieties of NSCLC by opening up opportunities for patients with very limited options. Physicians outline the ease of administration of this new therapy along with a well-tolerated profile of adverse reactions.

 

Future Directions of Research

This present study attempts to assess the value of CRIZOCENT 250 mg for use in early-stage lung cancer and other orphan cancers. New biomarkers being tested would ultimately allow better selection of patients. Current trials assess the role of CRIZOCENT combined with radiotherapy and other targeted therapies.

 

Conclusion:

CRIZOCENT 250 mg has brought new hope to patients with advanced NSCLC harboring specific ALK or ROS1 mutations. Its new mode of action promises better outcomes for them. Many ongoing studies will further expand its indication and benefit more cancer patients in the near future.

 

 

See more Oncology medicine visit our Shop